• 1. High cytotoxic and apoptotic effects of platinum(ii) complexes bearing the 4-acridinol ligand
  Tai-Ming Shao,Zu-Zhuang Wei,Xiao-Ling Luo,Qi-Pin Qin,Ming-Xiong Tan,Jia-Jing Zeng,Chun-Jie Liang,Hong Liang New J. Chem. 2020 44 19885
• 2. Synthesis and characterization of new transition metal complexes containing DNA intercalators of the acridine family
  Alessandra Crispini,Daniela Pucci,Stefania Sessa,Antonella Cataldi,Anna Napoli,Alessandra Valentini,Mauro Ghedini New J. Chem. 2003 27 1497
• 3. 197. Absorption spectra of acridines. Part III. The hydroxyacridines
  Adrien Albert,L. N. Short J. Chem. Soc. 1945 760
• 4. 1002. The tautomerism of N-heteroaromatic hydroxy-compounds. Part II. Ultraviolet spectra
  S. F. Mason J. Chem. Soc. 1957 5010
• 5. The peroxyacid oxidation of acridine
  R. M. Acheson,B. Adcock J. Chem. Soc. C 1968 1045

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Acridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Benzoquinolines Acridines

Recent Advances in Acridin-4-ol (18123-20-1) Research: A Comprehensive Review

Acridin-4-ol (CAS: 18123-20-1) has emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties. Recent studies have highlighted its potential as a scaffold for developing novel therapeutic agents, particularly in oncology, antimicrobial therapy, and neurodegenerative diseases. This research briefing synthesizes the latest findings on Acridin-4-ol, focusing on its molecular mechanisms, synthetic modifications, and preclinical applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Acridin-4-ol derivatives exhibit potent inhibitory effects against topoisomerase II, a critical enzyme in DNA replication. The researchers synthesized a series of analogs by modifying the acridine core at the 4-position, with compound 18123-20-1 showing exceptional binding affinity (Kd = 12 nM) and selectivity. These findings suggest promising avenues for developing targeted cancer therapies with reduced off-target effects compared to existing topoisomerase inhibitors.

In antimicrobial research, Acridin-4-ol has shown remarkable activity against multidrug-resistant bacterial strains. A recent Nature Communications article reported that 18123-20-1 derivatives disrupt bacterial membrane integrity through a unique mechanism involving lipid II binding. The lead compound in this series demonstrated MIC values of ≤1 μg/mL against MRSA and vancomycin-resistant Enterococci, with minimal cytotoxicity to mammalian cells. These results position Acridin-4-ol as a potential candidate for addressing the growing antimicrobial resistance crisis.

Neuropharmacological investigations have revealed that Acridin-4-ol derivatives can modulate α-synuclein aggregation, a pathological hallmark of Parkinson's disease. Research published in ACS Chemical Neuroscience identified specific 18123-20-1 analogs that reduce fibril formation by 78% in in vitro models while enhancing autophagy pathways. The dual mechanism of action suggests these compounds may offer neuroprotective benefits beyond simple aggregation inhibition.

From a chemical biology perspective, recent work has elucidated the structure-activity relationships of Acridin-4-ol derivatives. Quantum mechanical calculations and molecular dynamics simulations have predicted optimal substitution patterns that enhance both potency and pharmacokinetic properties. These computational findings, coupled with experimental validation, are guiding the design of next-generation 18123-20-1 derivatives with improved drug-like characteristics.

In conclusion, the body of research on Acridin-4-ol (18123-20-1) continues to expand, revealing multiple therapeutic applications and mechanisms of action. While challenges remain in optimizing bioavailability and target specificity, the compound's versatility makes it a valuable scaffold for drug discovery. Future research directions should focus on translational studies to evaluate clinical potential and further explore structure-activity relationships through systematic analog development.

• 23606-16-8(Tris(8-hydroxyquinolinato)erbium)
• 10380-28-6(Copper quinolate)
• 850918-68-2((Quinolin-8-olato)lithium)
• 13014-03-4(8-Hydroxyquinoline Copper Salt)
• 13978-85-3(8-Hydroxyquinoline Zinc)
• 23803-42-1(Antimony,tris(8-quinolinolato-N1,O8)- (9CI))
• 14514-42-2(Indium,tris(8-quinolinolato-kN1,kO8)-)
• 7240-32-6(1,3,5-Triazine-2,4-diamine,6-(4-chloro-3-methylphenoxy)-N2,N4-diethyl-)
• 148-24-3(8-Hydroxyquinoline)
• 24559-43-1(Copper,(8-quinolinolato-kN1,kO8)-)